Methionyl-tRNA Synthetase Overexpression is Associated with Poor Clinical Outcomes in Non-small Cell Lung Cancer

Overview

Journal BMC Cancer

Publisher Biomed Central

Specialty Oncology

Date 2017 Jul 7

PMID 28679377

Citations 22

Authors

Eun Young Kim

Ji Ye Jung

Arum Kim

Kwangsoo Kim

Yoon Soo Chang

Affiliations

Soon will be listed here.

Abstract

Background: Methionyl-tRNA synthetase (MRS) plays a critical role in initiating translation by transferring Met to the initiator tRNA (tRNA) and protection against ROS-mediated damage, suggesting that its overexpression is related to cancer growth and drug resistance. In this study, the clinical implication of MRS expression in non-small cell lung cancer (NSCLC) was evaluated.

Methods: Immunoblot and immunohistochemical (IHC) analyses were performed using tissue lysates and formalin-fixed paraffin embedded (FFPE) tissue blocks from wild type C57BL/6, LSL-Kras G12D, and LSL-Kras G12D:p53 mice. For human studies, 12 paired adjacent normal appearing lung tissue lysates and cancer tissue lysates, in addition to 231 FFPE tissue samples, were used.

Results: MRS was weakly expressed in the spleen and intestinal epithelium and only marginally expressed in the kidney, liver, and lungs of wild type C57BL/6 mice. On the other hand, MRS was strongly expressed in the neoplastic region of lung tissue from LSL-Kras G12D and LSL-Kras G12D:p53 mice. Immunoblot analysis of the human normal appearing adjacent and lung cancer paired tissue lysates revealed cancer-specific MRS overexpression, which was related to mTORC1 activity. IHC analysis of the 231 FFPE lung cancer tissue samples showed that MRS expression was frequently detected in the cytoplasm of lung cancer cells (179 out of 231, 77.4%), with a small proportion (73 out of 231, 31.6%) also showing nuclear expression. The proportion of cases with positive MRS expression was higher in the advanced pStage subgroup (P = 0.018, χ-test) and cases with MRS expression also had shorter DFS (161.6 vs 142.3, P = 0.014, log-rank test).

Conclusions: Taken together, MRS is frequently overexpressed in NSCLC. Moreover, MRS is related to mTORC1 activity and its overexpression is associated with poor clinical outcomes, indicating that it has potential as a putative therapeutic target.

Citing Articles

Valine aminoacyl-tRNA synthetase promotes therapy resistance in melanoma.

El-Hachem N, Leclercq M, Susaeta Ruiz M, Vanleyssem R, Shostak K, Korner P Nat Cell Biol. 2024; 26(7):1154-1164.

PMID: 38849541 PMC: 11252002. DOI: 10.1038/s41556-024-01439-2.

Prediction of Prognosis in Pancreatic Cancer According to Methionyl-tRNA Synthetase 1 Expression as Determined by Immunohistochemical Staining.

Jang S, Nahm J, Lee S, Cho J, Do M, Park J Cancers (Basel). 2023; 15(22).

PMID: 38001673 PMC: 10670752. DOI: 10.3390/cancers15225413.

High expression of VARS promotes the growth of multiple myeloma cells by causing imbalance in valine metabolism.

Shi R, Du W, He Y, Hu J, Yu H, Zhou W Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2023; 48(6):795-808.

PMID: 37587064 PMC: 10930441. DOI: 10.11817/j.issn.1672-7347.2023.220602.

The stress sensor GCN2 differentially controls ribosome biogenesis in colon cancer according to the nutritional context.

Piecyk M, Triki M, Laval P, Duret C, Fauvre J, Cussonneau L Mol Oncol. 2023; 18(9):2111-2135.

PMID: 37452637 PMC: 11467793. DOI: 10.1002/1878-0261.13491.

Induction of Reactive Bone Stromal Fibroblasts in 3D Models of Prostate Cancer Bone Metastases.

Windus L, Matigian N, Avery V Biology (Basel). 2023; 12(6).

PMID: 37372146 PMC: 10294842. DOI: 10.3390/biology12060861.

References

Levy C, Fisher D . Dual roles of lineage restricted transcription factors: the case of MITF in melanocytes. Transcription. 2011; 2(1):19-22. PMC: 3023642. DOI: 10.4161/trns.2.1.13650. View

Park S, Choi E, Kim S . Aminoacyl-tRNA synthetase-interacting multifunctional proteins (AIMPs): a triad for cellular homeostasis. IUBMB Life. 2010; 62(4):296-302. DOI: 10.1002/iub.324. View

Kim S, You S, Hwang D . Aminoacyl-tRNA synthetases and tumorigenesis: more than housekeeping. Nat Rev Cancer. 2011; 11(10):708-18. DOI: 10.1038/nrc3124. View

Ghanipour A, Jirstrom K, Ponten F, Glimelius B, Pahlman L, Birgisson H . The prognostic significance of tryptophanyl-tRNA synthetase in colorectal cancer. Cancer Epidemiol Biomarkers Prev. 2009; 18(11):2949-56. DOI: 10.1158/1055-9965.EPI-09-0456. View

Yannay-Cohen N, Carmi-Levy I, Kay G, Yang C, Han J, Kemeny D . LysRS serves as a key signaling molecule in the immune response by regulating gene expression. Mol Cell. 2009; 34(5):603-11. DOI: 10.1016/j.molcel.2009.05.019. View

Ko Y, Kim E, Kim T, Park H, Park H, Choi E . Glutamine-dependent antiapoptotic interaction of human glutaminyl-tRNA synthetase with apoptosis signal-regulating kinase 1. J Biol Chem. 2000; 276(8):6030-6. DOI: 10.1074/jbc.M006189200. View

Wolfson R, Chantranupong L, Saxton R, Shen K, Scaria S, Cantor J . Sestrin2 is a leucine sensor for the mTORC1 pathway. Science. 2015; 351(6268):43-8. PMC: 4698017. DOI: 10.1126/science.aab2674. View

Ray P, Jia J, Yao P, Majumder M, Hatzoglou M, Fox P . A stress-responsive RNA switch regulates VEGFA expression. Nature. 2008; 457(7231):915-9. PMC: 2858559. DOI: 10.1038/nature07598. View

Greenberg Y, King M, Kiosses W, Ewalt K, Yang X, Schimmel P . The novel fragment of tyrosyl tRNA synthetase, mini-TyrRS, is secreted to induce an angiogenic response in endothelial cells. FASEB J. 2008; 22(5):1597-605. DOI: 10.1096/fj.07-9973com. View

10.

Dehm S . mRNA splicing variants: exploiting modularity to outwit cancer therapy. Cancer Res. 2013; 73(17):5309-14. PMC: 3766449. DOI: 10.1158/0008-5472.CAN-13-0444. View

11.

Wakasugi K, Slike B, Hood J, Ewalt K, Cheresh D, Schimmel P . Induction of angiogenesis by a fragment of human tyrosyl-tRNA synthetase. J Biol Chem. 2002; 277(23):20124-6. DOI: 10.1074/jbc.C200126200. View

12.

I H, Cho J . Lung Cancer Biomarkers. Adv Clin Chem. 2015; 72:107-70. DOI: 10.1016/bs.acc.2015.07.003. View

13.

Kwon N, Kang T, Lee J, Kim H, Kim H, Hong J . Dual role of methionyl-tRNA synthetase in the regulation of translation and tumor suppressor activity of aminoacyl-tRNA synthetase-interacting multifunctional protein-3. Proc Natl Acad Sci U S A. 2011; 108(49):19635-40. PMC: 3241768. DOI: 10.1073/pnas.1103922108. View

14.

Siegel R, Miller K, Jemal A . Cancer statistics, 2015. CA Cancer J Clin. 2015; 65(1):5-29. DOI: 10.3322/caac.21254. View

15.

DeSantis C, Lin C, Mariotto A, Siegel R, Stein K, Kramer J . Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014; 64(4):252-71. DOI: 10.3322/caac.21235. View

16.

Aberle D, Abtin F, Brown K . Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial. J Clin Oncol. 2013; 31(8):1002-8. PMC: 3589698. DOI: 10.1200/JCO.2012.43.3110. View

17.

Hyun Y, Park H, Heo S, Yoon B, Nam S, Kim S . Rare variants in methionyl- and tyrosyl-tRNA synthetase genes in late-onset autosomal dominant Charcot-Marie-Tooth neuropathy. Clin Genet. 2013; 86(6):592-4. DOI: 10.1111/cge.12327. View

18.

Han J, Jeong S, Park M, Kim G, Kwon N, Kim H . Leucyl-tRNA synthetase is an intracellular leucine sensor for the mTORC1-signaling pathway. Cell. 2012; 149(2):410-24. DOI: 10.1016/j.cell.2012.02.044. View

19.

Aberle D, Berg C, Black W, Church T, Fagerstrom R, Galen B . The National Lung Screening Trial: overview and study design. Radiology. 2010; 258(1):243-53. PMC: 3009383. DOI: 10.1148/radiol.10091808. View

20.

Kikuchi T, Carbone D . Proteomics analysis in lung cancer: challenges and opportunities. Respirology. 2007; 12(1):22-8. DOI: 10.1111/j.1440-1843.2006.00957.x. View